var data={"title":"Pulmonary Langerhans cell histiocytosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pulmonary Langerhans cell histiocytosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 25, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary Langerhans cell histiocytosis (PLCH), also called eosinophilic granuloma of the lung, pulmonary Langerhans cell granulomatosis, and pulmonary histiocytosis X, is an uncommon interstitial lung disease that primarily affects young adults [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/1-7\" class=\"abstract_t\">1-7</a>]. The true incidence and prevalence are unknown. However, the diagnosis is made in less than 5 percent of lung biopsies and has been seen in less than 2 percent of the patients presenting to the Denver Specialized Center of Research program in Interstitial Lung Disease (a total of approximately 3000 patients over 14 years). No occupational or geographic predisposition has been reported, but nearly all affected individuals have a history of current or prior cigarette smoking. Thus, tobacco smoke is thought to be an etiologic factor.</p><p>Pulmonary Langerhans cell histiocytosis will be reviewed here. A general review of Langerhans cell histiocytosis, including the extrapulmonary manifestations of this disorder, is presented separately. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Langerhans cell, a differentiated cell of the monocyte-macrophage line, is the pathologic cell type of pulmonary Langerhans cell histiocytosis. It is distinguished by pale staining cytoplasm, a large nucleus and nucleoli, and, on electron microscopy, by classic pentalaminar cytoplasmic inclusions or Birbeck granules (X-bodies (<a href=\"image.htm?imageKey=HEME%2F60620\" class=\"graphic graphic_picture graphicRef60620 \">picture 1</a>)). Langerhans cells also demonstrate positive immunohistochemical staining for S100 protein. Another characteristic is the strong presence of CD1 antigen (CD1a) on the cell surface, a feature not observed in other cells of histiocytic origin [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Langerhans cells are normally found in the dermis, the reticuloendothelial system, the lung, and the pleura. They can be found in association with cigarette smoking in otherwise healthy individuals and can also be seen in other pulmonary disorders, such as idiopathic pulmonary fibrosis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/8,9\" class=\"abstract_t\">8,9</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-idiopathic-pulmonary-fibrosis\" class=\"medical medical_review\">&quot;Pathogenesis of idiopathic pulmonary fibrosis&quot;</a>.)</p><p>In pulmonary Langerhans cell histiocytosis, the Langerhans cells are characteristically found in clusters and significantly outnumber those seen in other lung diseases. However, quantitative guidelines for the diagnosis of pulmonary Langerhans cell histiocytosis have not been established.</p><p>Early inflammatory lesions surround the smaller bronchioles and usually contain an admixture of eosinophils, lymphocytes, and neutrophils (<a href=\"image.htm?imageKey=PULM%2F55413\" class=\"graphic graphic_picture graphicRef55413 \">picture 2</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/10\" class=\"abstract_t\">10</a>]. However, since eosinophils are not a prominent part of the pathology and the lesions are often devoid of eosinophils, the older term eosinophilic granuloma is a misnomer. These lesions may also involve pulmonary arterioles and venules (<a href=\"image.htm?imageKey=PULM%2F58695\" class=\"graphic graphic_picture graphicRef58695 \">picture 3</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Three other pathologic features that may be seen in pulmonary Langerhans cell histiocytosis have been reemphasized [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/11,12\" class=\"abstract_t\">11,12</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pseudo-desquamative interstitial pneumonia (DIP), characterized by the accumulation of alveolar macrophages in the pulmonary parenchyma in between the typical lesions containing Langerhans cells. (See <a href=\"topic.htm?path=idiopathic-interstitial-pneumonias-clinical-manifestations-and-pathology#H7\" class=\"medical medical_review\">&quot;Idiopathic interstitial pneumonias: Clinical manifestations and pathology&quot;, section on 'Desquamative interstitial pneumonia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Respiratory (&quot;smokers&quot;) bronchiolitis, characterized by pigmented macrophages filling the lumen of bronchioles and the surrounding alveolar spaces. (See <a href=\"topic.htm?path=respiratory-bronchiolitis-associated-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Respiratory bronchiolitis-associated interstitial lung disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intraluminal fibrosis, characterized by mural incorporation, alveolar obliteration, and intraluminal buds. This finding supports the hypothesis that intraluminal fibrosis is a mechanism for alveolar collapse with progression to interstitial fibrosis and lung remodeling [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p>There is often a predominance of disease in the mid to upper zones of the lung, in contrast to the typical lower zone predominance of idiopathic pulmonary fibrosis. Lesions frequently extend widely into the parenchyma of the lung surrounding the bronchovascular structures, producing the so-called <strong>stellate lesions</strong> that are characteristic of this disorder (<a href=\"image.htm?imageKey=PULM%2F52774%7EPULM%2F71884%7EPULM%2F51661\" class=\"graphic graphic_picture graphicRef52774 graphicRef71884 graphicRef51661 \">picture 4A-C</a>). Interstitial fibrosis and small cyst formation occur with advancing disease; the mechanism for cyst formation is unknown [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Older histopathological lesions can be relatively acellular. As a result, the eventual diffuse interstitial pathology can be difficult to distinguish from other forms of end-stage pulmonary fibrosis, with extensive areas of fibrosis and honeycombing accompanied by cystic lesions.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of pulmonary Langerhans cell histiocytosis is unknown. Several abnormalities in immune function have been found, including [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/15,16\" class=\"abstract_t\">15,16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A nonspecific increase in IgG in bronchoalveolar lavage fluid</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immune complexes in the circulation and bound to tissue</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormalities in T-cell function</p><p/><p>Although these factors may be important in the pathophysiology of pulmonary Langerhans cell histiocytosis, they may also represent nonspecific generalized activation of immune effector cells [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Role of cigarette smoking</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The near universal association of pulmonary Langerhans cell histiocytosis (PLCH) with cigarette smoking strongly implies some causative role [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/12,17\" class=\"abstract_t\">12,17</a>]. In contrast, there does <strong>not</strong> appear to be an association of smoking with extrapulmonary Langerhans cell histiocytosis. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One hypothesis is that increased bombesin-like peptide production plays a central role (<a href=\"image.htm?imageKey=PULM%2F57136\" class=\"graphic graphic_figure graphicRef57136 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/18\" class=\"abstract_t\">18</a>]. Bombesin is a neuropeptide produced by neuroendocrine cells, which are increased in the lungs of smokers [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/19\" class=\"abstract_t\">19</a>]. Bombesin-like peptides are chemotactic for monocytes, mitogenic for epithelial cells and fibroblasts, and they stimulate cytokine secretion [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/18,20\" class=\"abstract_t\">18,20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tobacco glycoprotein, a constituent of tobacco, is an immunostimulant that induces lymphocyte differentiation and lymphokine production. Tobacco glycoprotein and other regulatory glycopeptides (eg, GM-CSF) may contribute to disease pathogenesis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Finally, PLCH may represent a reactive polyclonal process that is induced by antigens in cigarette smoke. This would distinguish it from the other systemic forms of Langerhans cell histiocytosis, which have been shown to be the result of a monoclonal proliferation of Langerhans cell [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"headingAnchor\" id=\"H1258195\"><span class=\"h2\">Role of malignancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PLCH is regarded as a non-neoplastic process associated with smoking. However, sequencing studies suggest that a subset of PLCH cases might be a clonal process associated with a BRAF V600E mutation [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/23\" class=\"abstract_t\">23</a>]. Somatic BRAF V600E mutations have been found in a number of benign and malignant tumors and may play a role in the development of cancer. It has been shown that a subset of PLCH patents have BRAF V600E expression suggesting that PLCH may be a clonal proliferative process, in which cigarette smoking might play a role [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/24\" class=\"abstract_t\">24</a>]. However, the characteristics of BRAF mutations associated with lung cancer are described separately. (See <a href=\"topic.htm?path=personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer#H163136609\" class=\"medical medical_review\">&quot;Personalized, genotype-directed therapy for advanced non-small cell lung cancer&quot;, section on 'BRAF mutation'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of pulmonary Langerhans cell histiocytosis (PLCH) occur in young adults between 20 and 40 years of age (<a href=\"image.htm?imageKey=PULM%2F69932\" class=\"graphic graphic_figure graphicRef69932 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/25-27\" class=\"abstract_t\">25-27</a>]. There is an equal gender distribution, though women tend to present at an older age. Caucasians are affected more commonly than individuals of African or Asian descent. The duration of illness is usually less than one year prior to diagnosis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/1-4\" class=\"abstract_t\">1-4</a>].</p><p>Patients with PLCH present to medical attention in one of several ways [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/10,14\" class=\"abstract_t\">10,14</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With abnormalities incidentally detected on chest radiographs.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following a spontaneous pneumothorax.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With respiratory or constitutional symptoms, especially fever or weight loss.</p><p/><p>When patients present with symptoms, the most common symptoms include [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/4,6,10,27-31\" class=\"abstract_t\">4,6,10,27-31</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonproductive cough (56 to 70 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dyspnea (40 to 87 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest pain, which is frequently pleuritic (10 to 21 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fatigue (approximately 30 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Weight loss (20 to 30 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever (15 percent)</p><p/><p>The physical examination is usually unremarkable. Crackles and digital clubbing are uncommonly found on examination [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/28,32\" class=\"abstract_t\">28,32</a>]. Routine laboratory studies are usually unrevealing, and the peripheral eosinophil count is normal. (See <a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-clinical-evaluation\" class=\"medical medical_review\">&quot;Approach to the adult with interstitial lung disease: Clinical evaluation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with PLCH are at risk for a variety of thoracic and extrathoracic complications:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent spontaneous pneumothorax occurs in 15 to 25 percent of patients [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/33\" class=\"abstract_t\">33</a>]. Pleural thickening or effusion is rarely seen in the absence of a previous pneumothorax.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary arteriopathy and veno-occlusive disease can occur independently from parenchymal and airway disease, and may impair diffusing capacity and exercise capacity to a degree disproportionate to radiographic findings [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p>Pulmonary hypertension appears to be common among patients with PLCH, even in the absence of overt symptoms of right heart failure. An echocardiographic study of patients with histologically proven PLCH noted a resting peak pulmonary artery pressure &ge;35 mmHg in 15 of 17 patients (88 percent) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/35\" class=\"abstract_t\">35</a>]. The development of pulmonary hypertension was strongly associated with increased mortality, suggesting that severe pulmonary hypertension is not limited to patients with end-stage pulmonary disease.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemoptysis is occasionally reported (13 percent) and should prompt consideration of superimposed infection (eg, Aspergillus) or tumor [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/29,36\" class=\"abstract_t\">29,36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A number of malignant and nonmalignant tumors have been found in association with pulmonary Langerhans cell histiocytosis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/37-41\" class=\"abstract_t\">37-41</a>]. These include bronchogenic carcinoma (5 percent of patients), Hodgkin and non-Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/41\" class=\"abstract_t\">41</a>], pulmonary carcinoid tumor, and mediastinal ganglioneuroma. The malignancy may precede, follow, or occur concomitantly with the diagnosis of pulmonary Langerhans cell histiocytosis. The carcinogenic effect of cigarette smoke is probably the cause of some of these tumors.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cystic bone lesions are present in 4 to 20 percent of patients and may produce localized pain or a pathologic bone fracture. Skeletal involvement may precede the more typical pulmonary manifestations, and may be the sole manifestation of Langerhans cell histiocytosis. The radiographic pattern on bone films is not diagnostic. In most instances, the lesions are solitary and involve the flat bones. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diabetes insipidus, secondary to hypothalamic involvement, is seen in approximately 15 percent of patients, and is believed to portend a worse prognosis.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DIAGNOSTIC EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The signs and symptoms of pulmonary Langerhans cell histiocytosis are nonspecific and often point to other, more common pulmonary diagnoses. However, a history of recurrent pneumothorax, diabetes insipidus, or bone pain can be helpful in suggesting the diagnosis. A current or past smoking history is a consistent (but not essential) historical feature.</p><p>Most evaluations for pulmonary Langerhans cell histiocytosis are prompted after an abnormal chest roentgenogram is obtained. High resolution computed tomography (HRCT) of the chest, if classic, can be diagnostic, and therefore should be obtained in all patients suspected of having the disease [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/42\" class=\"abstract_t\">42</a>]. The differential diagnosis on chest CT scan includes pulmonary lymphangioleiomyomatosis, tuberous sclerosis, hypersensitivity pneumonitis, sarcoidosis, and endstage idiopathic pulmonary fibrosis. (See <a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-diagnostic-testing\" class=\"medical medical_review\">&quot;Approach to the adult with interstitial lung disease: Diagnostic testing&quot;</a> and <a href=\"topic.htm?path=diagnostic-approach-to-the-adult-with-cystic-lung-disease\" class=\"medical medical_review\">&quot;Diagnostic approach to the adult with cystic lung disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The radiographic appearance of pulmonary Langerhans cell histiocytosis can be very characteristic, if not diagnostic. A combination of the following features is felt to be highly specific for pulmonary Langerhans cell histiocytosis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/43-46\" class=\"abstract_t\">43-46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ill-defined or stellate nodules (2 to 10 mm in size)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reticular and nodular opacities</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Upper zone cysts or honeycombing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preservation of lung volume</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Costophrenic angle sparing</p><p/><p>The reticular and nodular opacities are typically seen in the middle to upper lung zones (<a href=\"image.htm?imageKey=PULM%2F82197\" class=\"graphic graphic_diagnosticimage graphicRef82197 \">image 1</a>). The total lung volume is normal, although both hyperinflation and reduced volume can occur (<a href=\"image.htm?imageKey=PULM%2F60751\" class=\"graphic graphic_diagnosticimage graphicRef60751 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/29,47\" class=\"abstract_t\">29,47</a>]. Hilar or mediastinal adenopathy is rare and should prompt consideration of malignancy as a secondary diagnosis. Pleural thickening is most often due to treated pneumothorax. Bone lesions can occur in any bone, including the ribs. (See <a href=\"topic.htm?path=evaluation-of-diffuse-lung-disease-by-conventional-chest-radiography\" class=\"medical medical_review\">&quot;Evaluation of diffuse lung disease by conventional chest radiography&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Computed tomography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HRCT of the chest is a particularly useful diagnostic tool in patients with suspected pulmonary Langerhans cell histiocytosis (PLCH). The combination of multiple cysts and nodules, with a mid to upper zone predominance, and interstitial thickening in a young smoker is so characteristic that it can be diagnostic of PLCH (<a href=\"image.htm?imageKey=PULM%2F58182%7EPULM%2F69891%7EPULM%2F72698\" class=\"graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698 \">image 3A-C</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/44,48\" class=\"abstract_t\">44,48</a>]. The nodules can be poorly or well defined, but occasionally they can be large and bizarrely shaped. Honeycombing can be seen in advanced disease. The degree of cyst formation is often under appreciated by routine chest radiography. (See <a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs#H28\" class=\"medical medical_review\">&quot;High resolution computed tomography of the lungs&quot;, section on 'Langerhans cell histiocytosis'</a>.)</p><p>Serial chest CT scanning suggests a sequence of progression from nodules to cavitating nodules to cystic lesions [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/49,50\" class=\"abstract_t\">49,50</a>]. This progression may explain a number of &quot;spontaneous remissions&quot; reported before the routine use of HRCT. The value of serial lung CT scanning in the routine follow-up of patients has been questioned [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Fluorodeoxyglucose-PET scan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fluorodeoxyglucose-PET (FDG-PET) scans may show increased uptake in patients with PLCH, particularly when obtained early in the course of disease. This was evaluated in a series of 11 patients with PLCH, five of whom had abnormal FDG uptake in the lungs [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/52\" class=\"abstract_t\">52</a>]. The patients with FDG-PET positivity were more likely to have nodular radiographic pattern, suggesting earlier disease; those with negative FDG-PET scans were more likely to have a cystic pattern and fewer nodules, suggesting later disease.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Physiologic testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, total lung capacity and expiratory flow rates are well-preserved in PLCH [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/10,29,53-55\" class=\"abstract_t\">10,29,53-55</a>]. Predominantly nodular disease is usually associated with normal or restrictive pulmonary function tests, whereas cystic disease is more likely to be associated with abnormal physiologic testing [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/50\" class=\"abstract_t\">50</a>]. The following abnormalities can be seen:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diffusing capacity is disproportionately reduced in most patients [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/29\" class=\"abstract_t\">29</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A subgroup of patients shows predominantly restrictive disease, with reduced total lung volume and increased elastic recoil.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Airflow limitation and hyperinflation occur in a minority of patients, typically in patients with more advanced, cystic disease [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/50,51\" class=\"abstract_t\">50,51</a>]. Airflow limitation is sometimes associated with reactive airways and significant improvement after bronchodilator administration [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/8,29,47,54\" class=\"abstract_t\">8,29,47,54</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measurement of arterial blood gases in the patient at rest usually shows a normal alveolar-arterial oxygen difference and a normal PaCO<sub>2</sub> and pH. Thus, resting arterial blood gases are an insensitive indicator of disease.</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Exercise physiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with PLCH generally demonstrate a limitation in activity and exercise intolerance out of proportion to pulmonary function abnormalities [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/29,56\" class=\"abstract_t\">29,56</a>]. Markedly decreased exercise capacity, as measured by either work achieved or oxygen utilization (VO<sub>2</sub>) at maximal exercise, is commonly present. The oxygen pulse at maximal exercise and at anaerobic threshold is reduced in most patients. The maximal ventilatory response is excessive (but not limiting) for the maximal level of work.</p><p>Gas exchange abnormalities, reflected by a rising alveolar-arterial oxygen difference with increasing exercise, are seen in the majority of patients. In most patients, dead space to tidal volume ratio <span class=\"nowrap\">(VD/VT)</span> is either abnormally elevated at rest or fails to decrease with exercise. This abnormality suggests either pathologic or functional involvement of the pulmonary vasculature by the disease process.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Bronchoalveolar lavage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The finding of more than 5 percent Langerhans cells (CD-1a positive) on bronchoalveolar lavage (BAL) strongly suggests the diagnosis of PLCH (<a href=\"image.htm?imageKey=PULM%2F106383\" class=\"graphic graphic_diagnosticimage graphicRef106383 \">image 4</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/1,5,57-60\" class=\"abstract_t\">1,5,57-60</a>], but quantitative criteria for the diagnosis have not been conclusively established. A finding of less than 5 percent CD-1a positive cells does not exclude the diagnosis of PLCH. (See <a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of bronchoalveolar lavage in diagnosis of interstitial lung disease&quot;</a>.)</p><p>Lower proportions of Langerhans cells can be seen in other settings (current smokers, patients with other interstitial lung disorders, bronchioloalveolar carcinoma). Therefore, the mere presence of Langerhans cells on BAL is of little diagnostic value.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Tissue confirmation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When tissue confirmation of the diagnosis is sought, transbronchial biopsy can be sufficient to make the diagnosis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/61\" class=\"abstract_t\">61</a>]. However, a substantial number of false negative or nondiagnostic biopsies result from sampling error and insufficient tissue. Video thoracoscopic lung biopsy, on the other hand, is generally definitive. (See <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;</a>.)</p><p>Langerhans cells can be recognized by their characteristic staining for S-100 protein [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/62,63\" class=\"abstract_t\">62,63</a>]. These cells are also OKT-6 (CD1a) positive and demonstrate staining with the monoclonal antibody MT-1 [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/64\" class=\"abstract_t\">64</a>]. Tissue immunostaining with the monoclonal antibody OKT-6 (CD1a) distinguishes Langerhans cells from other histiocytes, and can be a useful adjunct in difficult cases [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/65\" class=\"abstract_t\">65</a>]. Immunostaining can be performed on routinely fixed tissue and is less expensive than electron microscopy.</p><p>In cases of progressive disease with extensive fibrosis, the number of Langerhans cells in either tissue specimens or bronchoalveolar lavage fluid decreases dramatically. Diagnosis at this stage can be difficult regardless of the laboratory methods used. In most cases, the combination of transbronchial lung biopsy and BAL supplemented with the identification of CD-1a positive cells in tissue and BAL fluid is highly likely to result in the correct diagnosis [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/14,66\" class=\"abstract_t\">14,66</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial focus of any therapeutic regimen in patients with pulmonary Langerhans cell histiocytosis (PLCH) is cessation of smoking [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/67\" class=\"abstract_t\">67</a>]. (See <a href=\"topic.htm?path=overview-of-smoking-cessation-management-in-adults\" class=\"medical medical_review\">&quot;Overview of smoking cessation management in adults&quot;</a>.)</p><p>Immunosuppressive therapies, such as glucocorticoids and cytotoxic agents, are of <strong>limited</strong> value [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/47,68,69\" class=\"abstract_t\">47,68,69</a>]. Unfortunately, no studies comparing different treatments in adults with lung disease have been performed [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/70\" class=\"abstract_t\">70</a>]. In our experience, only patients with prominent nodular opacities respond to glucocorticoid therapy. Case reports have described improvement in PLCH following treatment with <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a> (2-chlorodeoxyadenosine), a chemotherapeutic agent cytotoxic for lymphocyte and monocyte cells [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/71-75\" class=\"abstract_t\">71-75</a>]. The use of cladribine to treat Langerhans cell histiocytosis is discussed separately. </p><p>Identification of BRAF<sup>V600E</sup> expression in LCH and in 35 to 50 percent of people with PLCH has led to the use of targeted therapy with inhibitors of mutated BRAF [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/24,76\" class=\"abstract_t\">24,76</a>]. Treatment with a BRAF inhibitor, <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">Vemurafenib</a>, resulted in stabilization of disease in the majority of patients with Erdheim&ndash;Chester disease and LCH while none experienced disease progression during treatment. However, nearly all of these patients experience relapse upon discontinuation of therapy. The role of this treatment in PLCH remains to be defined [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/77\" class=\"abstract_t\">77</a>]. (See <a href=\"topic.htm?path=treatment-of-langerhans-cell-histiocytosis#H6873611\" class=\"medical medical_review\">&quot;Treatment of Langerhans cell histiocytosis&quot;, section on 'Relapsed or refractory disease'</a>.)</p><p>Radiation therapy for symptomatic bone lesions can be palliative, but it is not useful in treatment of the pulmonary manifestations.</p><p>The efficacy of treatment of pulmonary hypertension complicating PLCH was examined in a series of 12 patients [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/30\" class=\"abstract_t\">30</a>]. Therapy with an endothelin receptor antagonist, a phosphodiesterase 5 inhibitor, <a href=\"topic.htm?path=iloprost-drug-information\" class=\"drug drug_general\">iloprost</a>, or a combination led to modest improvements in mean pulmonary arterial pressure (from 56 &plusmn; 14 to 45 &plusmn; 12 mmHg) and pulmonary vascular resistance (from 701 &plusmn; 239 to 469 &plusmn; 210 dynes-sec-cm<sup>-5</sup>) between baseline and follow up evaluations. No significant worsening of oxygenation was observed with treatment. Case reports have suggested that PLCH-associated pulmonary hypertension may, in certain instances, be responsive to advanced pulmonary hypertension therapies [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/78,79\" class=\"abstract_t\">78,79</a>]. </p><p>Lung transplantation should be considered in patients with advanced, progressive disease unless contraindications are present. Recurrence of the condition in the transplanted lung may occur, but it is unclear if this affects overall posttransplant survival [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/80,81\" class=\"abstract_t\">80,81</a>]. (See <a href=\"topic.htm?path=lung-transplantation-general-guidelines-for-recipient-selection\" class=\"medical medical_review\">&quot;Lung transplantation: General guidelines for recipient selection&quot;</a>.)</p><p>Clinical trials of therapy for LCH are ongoing, and enrollment may be appropriate for selected patients. In the United States, the Histiocyte Society initiated a series of protocols for treatment of adults with LCH in 2001. Treatment protocols and other information can be obtained through the Histiocytosis Association of America (1-800-548-2758 or <a href=\"http://www.histio.org/&amp;token=+mtJJc/IdrUJXLZzfEZwUNvDuyYCSdYrjORoAiDH1qQ=&amp;TOPIC_ID=4334\" target=\"_blank\" class=\"external\">www.histio.org</a>) and at <a href=\"http://clinicaltrials.gov/&amp;token=YbJELcAW9G3aZfZrjTwglubdGkNLI6vF+UUqouKTYUezNDuyrLCVJ8CPUNOYDvHP&amp;TOPIC_ID=4334\" target=\"_blank\" class=\"external\">http://clinicaltrials.gov/</a>. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The overall survival for pulmonary Langerhans cell histiocytosis (PLCH) is good with most reports showing a five-year survival estimate of &gt;75 percent [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/25,30,82,83\" class=\"abstract_t\">25,30,82,83</a>]. However, the natural history of PLCH is variable, with some patients experiencing spontaneous remission of symptoms and others progressing to end-stage fibrotic lung disease (<a href=\"image.htm?imageKey=PULM%2F71979\" class=\"graphic graphic_figure graphicRef71979 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/31\" class=\"abstract_t\">31</a>]. Both smoking status and the radiographic picture can affect disease progression. Most subjects demonstrate gradual progression with continued cigarette smoking, while the disease may regress with the cessation of smoking [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/67\" class=\"abstract_t\">67</a>]. Patients with radiographic sparing of the costophrenic angle are more likely to remain stable or improve compared to those with costophrenic angle involvement [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/45\" class=\"abstract_t\">45</a>]. Pulmonary hypertension is common, and is independently associated with decreased survival [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/35\" class=\"abstract_t\">35</a>].</p><p>In a review of clinical outcomes drawn from the collected Mayo Clinic experience of 102 adult patients with pulmonary LCH, median survival (12.5 years from diagnosis) was shorter than for age-matched controls in the general population (<a href=\"image.htm?imageKey=PULM%2F72679\" class=\"graphic graphic_figure graphicRef72679 \">figure 4</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/25\" class=\"abstract_t\">25</a>]. Estimated five and ten-year survival rates were 74 and 64 percent, respectively. Nearly half (15 of 33) of the deaths that occurred during the follow-up period were attributed to respiratory failure. The other major cause of death was malignancy, primarily of hematologic or epithelial origin.</p><p>In a separate study of 29 patients with PLCH and pulmonary arterial hypertension, the one, three, and five-year survival estimates were 96, 92, and 73 percent, respectively [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/30\" class=\"abstract_t\">30</a>]. </p><p>Follow-up testing every three months in the first year after diagnosis may be useful in identifying patients who are likely to develop progressive disease [<a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/3,25\" class=\"abstract_t\">3,25</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary Langerhans cell histiocytosis (PLCH) is an uncommon interstitial lung disease that primarily affects young adults. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The near universal association of PLCH with cigarette smoking strongly implies a causative role. In contrast, there does <strong>not</strong> appear to be an association of smoking with extrapulmonary Langerhans cell histiocytosis. (See <a href=\"#H3\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Langerhans cell, a differentiated cell of the monocyte-macrophage line, is the pathologic cell type of pulmonary Langerhans cell histiocytosis. These cells are positive on immunostaining with the monoclonal antibody OKT-6 that recognizes CD1 antigen (CD1a). Histopathologic lesions frequently extend widely into the parenchyma of the lung surrounding the bronchovascular structures, producing the so-called <strong>stellate lesions</strong> that are characteristic of this disorder (<a href=\"image.htm?imageKey=PULM%2F52774%7EPULM%2F71884%7EPULM%2F51661\" class=\"graphic graphic_picture graphicRef52774 graphicRef71884 graphicRef51661 \">picture 4A-C</a>). (See <a href=\"#H2\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients usually present following a spontaneous pneumothorax or with a nonproductive cough, dyspnea, or constitutional symptoms, especially fever or weight loss. Recurrent spontaneous pneumothorax occurs in 15 to 25 percent of patients. (See <a href=\"#H5\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients may also have extrapulmonary histiocytosis with diabetes insipidus or cystic bone lesions. Pulmonary hypertension appears to be common among patients with PLCH, even in the absence of overt symptoms of right heart failure. (See <a href=\"#H6\" class=\"local\">'Complications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A high resolution computed tomography (HRCT) scan of the chest showing a combination of multiple cysts and nodules, with a mid to upper zone predominance, and interstitial thickening in a young smoker is so characteristic that it can be diagnostic of pulmonary Langerhans cell histiocytosis (<a href=\"image.htm?imageKey=PULM%2F58182%7EPULM%2F69891%7EPULM%2F72698\" class=\"graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698 \">image 3A-C</a>). (See <a href=\"#H8\" class=\"local\">'Imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary function tests may be normal or may show reduced lung volumes and a reduced diffusing capacity. Airflow limitation and hyperinflation occur in a minority of patients, typically in patients with more advanced, cystic disease. (See <a href=\"#H11\" class=\"local\">'Physiologic testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the radiographic pattern is nondiagnostic, the combination of transbronchial lung biopsy and bronchoalveolar lavage (BAL) showing an increase in the number of CD-1a positive cells strongly suggests PLCH, especially when more than 5 percent of BAL cells are CD1a positive (<a href=\"image.htm?imageKey=PULM%2F106383\" class=\"graphic graphic_diagnosticimage graphicRef106383 \">image 4</a>). (See <a href=\"#H14\" class=\"local\">'Tissue confirmation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The main focus of any therapeutic regimen in patients with pulmonary Langerhans cell histiocytosis is cessation of smoking. (See <a href=\"#H15\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The optimal therapy for patients who do not improve with smoking cessation is not known. In our experience, only patients with prominent nodular opacities respond to glucocorticoid therapy. Radiation therapy is not useful in treatment of the pulmonary manifestations, although it can be palliative for symptomatic bone lesions. (See <a href=\"#H15\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Information about clinical trials for patients with PLCH can be obtained at <a href=\"http://www.histio.org/&amp;token=+mtJJc/IdrUJXLZzfEZwUNvDuyYCSdYrjORoAiDH1qQ=&amp;TOPIC_ID=4334\" target=\"_blank\" class=\"external\">www.histio.org</a> or <a href=\"http://clinicaltrials.gov/&amp;token=YbJELcAW9G3aZfZrjTwglubdGkNLI6vF+UUqouKTYUezNDuyrLCVJ8CPUNOYDvHP&amp;TOPIC_ID=4334\" target=\"_blank\" class=\"external\">http://clinicaltrials.gov</a>. (See <a href=\"#H15\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/1\" class=\"nounderline abstract_t\">Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans' cell histiocytosis. Thorax 2000; 55:405.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/2\" class=\"nounderline abstract_t\">Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000; 342:1969.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/3\" class=\"nounderline abstract_t\">Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med 2004; 25:561.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/4\" class=\"nounderline abstract_t\">Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest 2003; 123:1673.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/5\" class=\"nounderline abstract_t\">Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006; 27:1272.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/6\" class=\"nounderline abstract_t\">Wei P, Lu HW, Jiang S, et al. Pulmonary langerhans cell histiocytosis: case series and literature review. Medicine (Baltimore) 2014; 93:e141.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/7\" class=\"nounderline abstract_t\">Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med 2015; 26:351.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/8\" class=\"nounderline abstract_t\">Casolaro MA, Bernaudin JF, Saltini C, et al. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137:406.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/9\" class=\"nounderline abstract_t\">Soler P, Moreau A, Basset F, Hance AJ. Cigarette smoking-induced changes in the number and differentiated state of pulmonary dendritic cells/Langerhans cells. Am Rev Respir Dis 1989; 139:1112.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/10\" class=\"nounderline abstract_t\">Basset F, Corrin B, Spencer H, et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118:811.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/11\" class=\"nounderline abstract_t\">Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 1993; 17:971.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/12\" class=\"nounderline abstract_t\">Vassallo R, Jensen EA, Colby TV, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest 2003; 124:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/13\" class=\"nounderline abstract_t\">Fukuda Y, Basset F, Soler P, et al. Intraluminal fibrosis and elastic fiber degradation lead to lung remodeling in pulmonary Langerhans cell granulomatosis (histiocytosis X). Am J Pathol 1990; 137:415.</a></li><li class=\"breakAll\">Vassallo R, Limper AH. Pulmonary Langerhans cell histiocytosis. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.838.</li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/15\" class=\"nounderline abstract_t\">Rowden G. The Langerhans cell. Crit Rev Immunol 1981; 3:95.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/16\" class=\"nounderline abstract_t\">King TE Jr, Schwarz MI, Dreisin RE, et al. Circulating immune complexes in pulmonary eosinophilic granuloma. Ann Intern Med 1979; 91:397.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/17\" class=\"nounderline abstract_t\">Sch&ouml;nfeld N, Dirks K, Costabel U, et al. A prospective clinical multicentre study on adult pulmonary Langerhans' cell histiocytosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:132.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/18\" class=\"nounderline abstract_t\">Aguayo SM, King TE Jr, Waldron JA Jr, et al. Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest 1990; 86:838.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/19\" class=\"nounderline abstract_t\">Aguayo SM, Kane MA, King TE Jr, et al. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest 1989; 84:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/20\" class=\"nounderline abstract_t\">Petronilho F, Roesler R, Schwartsmann G, Dal Pizzol F. Gastrin-releasing peptide receptor as a molecular target for inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6:197.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/21\" class=\"nounderline abstract_t\">Youkeles LH, Grizzanti JN, Liao Z, et al. Decreased tobacco-glycoprotein-induced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med 1995; 151:145.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/22\" class=\"nounderline abstract_t\">Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol 2001; 25:630.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/23\" class=\"nounderline abstract_t\">Yousem SA, Dacic S, Nikiforov YE, Nikiforova M. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013; 143:1679.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/24\" class=\"nounderline abstract_t\">Roden AC, Hu X, Kip S, et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 2014; 38:548.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/25\" class=\"nounderline abstract_t\">Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002; 346:484.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/26\" class=\"nounderline abstract_t\">G&ouml;tz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res 2004; 9:510.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/27\" class=\"nounderline abstract_t\">Mason RH, Foley NM, Branley HM, et al. Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register. Thorax 2014; 69:766.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/28\" class=\"nounderline abstract_t\">Marcy TW, Reynolds HY. Pulmonary histiocytosis X. Lung 1985; 163:129.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/29\" class=\"nounderline abstract_t\">Crausman RS, Jennings CA, Tuder RM, et al. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996; 153:426.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/30\" class=\"nounderline abstract_t\">Le Pavec J, Lorillon G, Ja&iuml;s X, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/31\" class=\"nounderline abstract_t\">Tazi A, de Margerie C, Naccache JM, et al. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis 2015; 10:30.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/32\" class=\"nounderline abstract_t\">Epler GR, Carrington CB, Gaensler EA. Crackles (rales) in the interstitial pulmonary diseases. Chest 1978; 73:333.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/33\" class=\"nounderline abstract_t\">Mendez JL, Nadrous HF, Vassallo R, et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004; 125:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/34\" class=\"nounderline abstract_t\">Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161:216.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/35\" class=\"nounderline abstract_t\">Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79:1269.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/36\" class=\"nounderline abstract_t\">Knight RK. Haemoptysis in eosinophilic granuloma. Br J Dis Chest 1979; 73:181.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/37\" class=\"nounderline abstract_t\">Lombard CM, Medeiros LJ, Colby TV. Pulmonary histiocytosis X and carcinoma. Arch Pathol Lab Med 1987; 111:339.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/38\" class=\"nounderline abstract_t\">Sadoun D, Vaylet F, Valeyre D, et al. Bronchogenic carcinoma in patients with pulmonary histiocytosis X. Chest 1992; 101:1610.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/39\" class=\"nounderline abstract_t\">Tomashefski JF, Khiyami A, Kleinerman J. Neoplasms associated with pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1991; 115:499.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/40\" class=\"nounderline abstract_t\">Tsuji T, Nakamura S, Tanaka M. Pulmonary Langerhans cell histiocytosis associated with lingual carcinoma. Intern Med 2004; 43:713.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/41\" class=\"nounderline abstract_t\">Coli A, Bigotti G, Ferrone S. Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies. Virchows Arch A Pathol Anat Histopathol 1991; 418:369.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/42\" class=\"nounderline abstract_t\">Gupta N, Langenderfer D, McCormack FX, et al. Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective. Ann Am Thorac Soc 2017; 14:17.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/43\" class=\"nounderline abstract_t\">Aguayo SM, Schwarz MI, Mortenson RL. The role of the chest radiograph in the evaluation of disease severity and clinical course in eosinophilic granuloma. Am Rev Respir Dis 1990; 141:A61.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/44\" class=\"nounderline abstract_t\">Kulwiec EL, Lynch DA, Aguayo SM, et al. Imaging of pulmonary histiocytosis X. Radiographics 1992; 12:515.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/45\" class=\"nounderline abstract_t\">Lacronique J, Roth C, Battesti JP, et al. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax 1982; 37:104.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/46\" class=\"nounderline abstract_t\">Castoldi MC, Verrioli A, De Juli E, Vanzulli A. Pulmonary Langerhans cell histiocytosis: the many faces of presentation at initial CT scan. Insights Imaging 2014; 5:483.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/47\" class=\"nounderline abstract_t\">Sch&ouml;nfeld N, Frank W, Wenig S, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 1993; 60:38.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/48\" class=\"nounderline abstract_t\">Kim HJ, Lee KS, Johkoh T, et al. Pulmonary Langerhans cell histiocytosis in adults: high-resolution CT-pathology comparisons and evolutional changes at CT. Eur Radiol 2011; 21:1406.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/49\" class=\"nounderline abstract_t\">Brauner MW, Grenier P, Tijani K, et al. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology 1997; 204:497.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/50\" class=\"nounderline abstract_t\">Canuet M, Kessler R, Jeung MY, et al. Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis. Respiration 2007; 74:640.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/51\" class=\"nounderline abstract_t\">Tazi A, Marc K, Dominique S, et al. Serial computed tomography and lung function testing in pulmonary Langerhans' cell histiocytosis. Eur Respir J 2012; 40:905.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/52\" class=\"nounderline abstract_t\">Krajicek BJ, Ryu JH, Hartman TE, et al. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest 2009; 135:1542.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/53\" class=\"nounderline abstract_t\">Chusid, EL. Pulmonary eosinophilic granuloma: aspects of pulmonary function. Mt Sinai J Med 1961; 33:116.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/54\" class=\"nounderline abstract_t\">Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 1981; 60:385.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/55\" class=\"nounderline abstract_t\">HOFFMAN L, COHN JE, GAENSLER EA. Respiratory abnormalities in eosinophilic granuloma of the lung. Longterm study of five cases. N Engl J Med 1962; 267:577.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/56\" class=\"nounderline abstract_t\">Rolland-Debord C, Fry S, Giovannelli J, et al. Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis. PLoS One 2017; 12:e0170035.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/57\" class=\"nounderline abstract_t\">Harari S, Comel A. Pulmonary Langerhans cell Histiocytosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:253.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/58\" class=\"nounderline abstract_t\">Auerswald U, Barth J, Magnussen H. Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 1991; 169:305.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/59\" class=\"nounderline abstract_t\">Baqir M, Vassallo R, Maldonado F, et al. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol 2013; 20:309.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/60\" class=\"nounderline abstract_t\">Harari S, Torre O, Cassandro R, et al. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med 2012; 106:1286.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/61\" class=\"nounderline abstract_t\">Housini I, Tomashefski JF Jr, Cohen A, et al. Transbronchial biopsy in patients with pulmonary eosinophilic granuloma. Comparison with findings on open lung biopsy. Arch Pathol Lab Med 1994; 118:523.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/62\" class=\"nounderline abstract_t\">Ornvold K, Ralfkiaer E, Carstensen H. Immunohistochemical study of the abnormal cells in Langerhans cell histiocytosis (histiocytosis x). Virchows Arch A Pathol Anat Histopathol 1990; 416:403.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/63\" class=\"nounderline abstract_t\">Ye F, Huang SW, Dong HJ. Histiocytosis X. S-100 protein, peanut agglutinin, and transmission electron microscopy study. Am J Clin Pathol 1990; 94:627.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/64\" class=\"nounderline abstract_t\">Kahn HJ, Thorner PS. Monoclonal antibody MT1: a marker for Langerhans cell histiocytosis. Pediatr Pathol 1990; 10:375.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/65\" class=\"nounderline abstract_t\">Soler P, Chollet S, Jacque C, et al. Immunocytochemical characterization of pulmonary histiocytosis X cells in lung biopsies. Am J Pathol 1985; 118:439.</a></li><li class=\"breakAll\">King TE Jr. Bronchoscopy in interstitial lung disease. In: Textbook of Bronchoscopy, Feinsilver SH, Fein AM (Eds), Williams &amp; Wilkins, Baltimore 1995. p.185.</li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/67\" class=\"nounderline abstract_t\">Mogulkoc N, Veral A, Bishop PW, et al. Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999; 115:1452.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/68\" class=\"nounderline abstract_t\">Tsele E, Thomas DM, Chu AC. Treatment of adult Langerhans cell histiocytosis with etoposide. J Am Acad Dermatol 1992; 27:61.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/69\" class=\"nounderline abstract_t\">Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis--evolution and current approaches. Br J Cancer Suppl 1994; 23:S41.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/70\" class=\"nounderline abstract_t\">Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax 2017; 72:937.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/71\" class=\"nounderline abstract_t\">Lazor R, Etienne-Mastroianni B, Khouatra C, et al. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax 2009; 64:274.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/72\" class=\"nounderline abstract_t\">Aerni MR, Aubry MC, Myers JL, Vassallo R. Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker. Respir Med 2008; 102:316.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/73\" class=\"nounderline abstract_t\">Lorillon G, Bergeron A, Detourmignies L, et al. Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med 2012; 186:930.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/74\" class=\"nounderline abstract_t\">Epaud R, Ducou Le Pointe H, Fasola S, et al. Cladribine improves lung cysts and pulmonary function in a child with histiocytosis. Eur Respir J 2015; 45:831.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/75\" class=\"nounderline abstract_t\">Grobost V, Khouatra C, Lazor R, et al. Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis 2014; 9:191.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/76\" class=\"nounderline abstract_t\">Mourah S, How-Kit A, Meignin V, et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J 2016; 47:1785.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/77\" class=\"nounderline abstract_t\">Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/78\" class=\"nounderline abstract_t\">May A, Kane G, Yi E, et al. Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. Respir Med Case Rep 2015; 14:13.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/79\" class=\"nounderline abstract_t\">Fukuda Y, Miura S, Fujimi K, et al. Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension. Eur J Prev Cardiol 2014; 21:1481.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/80\" class=\"nounderline abstract_t\">Gabbay E, Dark JH, Ashcroft T, et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53:326.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/81\" class=\"nounderline abstract_t\">Habib SB, Congleton J, Carr D, et al. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax 1998; 53:323.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/82\" class=\"nounderline abstract_t\">Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Soci&eacute;t&eacute; de Pathologie Thoracique du Nord. Eur Respir J 1996; 9:2002.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis/abstract/83\" class=\"nounderline abstract_t\">Aric&ograve; M, Girschikofsky M, G&eacute;n&eacute;reau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39:2341.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4334 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Role of cigarette smoking</a></li><li><a href=\"#H1258195\" id=\"outline-link-H1258195\">Role of malignancy</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Complications</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">DIAGNOSTIC EVALUATION</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Imaging</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Computed tomography</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Fluorodeoxyglucose-PET scan</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">Physiologic testing</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">- Exercise physiology</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">Bronchoalveolar lavage</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Tissue confirmation</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">TREATMENT</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">PROGNOSIS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4334|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/82197\" class=\"graphic graphic_diagnosticimage\">- Langerhans histiocytosis PA I</a></li><li><a href=\"image.htm?imageKey=PULM/60751\" class=\"graphic graphic_diagnosticimage\">- Langerhans histiocytosis PA II</a></li><li><a href=\"image.htm?imageKey=PULM/58182\" class=\"graphic graphic_diagnosticimage\">- Langerhans histiocytosis CT I</a></li><li><a href=\"image.htm?imageKey=PULM/69891\" class=\"graphic graphic_diagnosticimage\">- Langerhans histiocytosis CT II</a></li><li><a href=\"image.htm?imageKey=PULM/72698\" class=\"graphic graphic_diagnosticimage\">- Pulmonary histiocytosis X CT</a></li><li><a href=\"image.htm?imageKey=PULM/106383\" class=\"graphic graphic_diagnosticimage\">- CD1a-positive cells in BAL fluid</a></li></ul></li><li><div id=\"PULM/4334|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/57136\" class=\"graphic graphic_figure\">- Smoking in pulm histiocytosis X</a></li><li><a href=\"image.htm?imageKey=PULM/69932\" class=\"graphic graphic_figure\">- Age pulmonary histiocytosis X</a></li><li><a href=\"image.htm?imageKey=PULM/71979\" class=\"graphic graphic_figure\">- Course pulmonary histiocytosis</a></li><li><a href=\"image.htm?imageKey=PULM/72679\" class=\"graphic graphic_figure\">- Survival pulmonary LCH</a></li></ul></li><li><div id=\"PULM/4334|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/60620\" class=\"graphic graphic_picture\">- Birbeck granules</a></li><li><a href=\"image.htm?imageKey=PULM/55413\" class=\"graphic graphic_picture\">- Histiocytosis X High power</a></li><li><a href=\"image.htm?imageKey=PULM/58695\" class=\"graphic graphic_picture\">- Early lesion in PHX</a></li><li><a href=\"image.htm?imageKey=PULM/52774\" class=\"graphic graphic_picture\">- Pulmonary histiocytosis X Low</a></li><li><a href=\"image.htm?imageKey=PULM/71884\" class=\"graphic graphic_picture\">- Stellate lesions I</a></li><li><a href=\"image.htm?imageKey=PULM/51661\" class=\"graphic graphic_picture\">- Stellate lesions II</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-clinical-evaluation\" class=\"medical medical_review\">Approach to the adult with interstitial lung disease: Clinical evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-diagnostic-testing\" class=\"medical medical_review\">Approach to the adult with interstitial lung disease: Diagnostic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-the-adult-with-cystic-lung-disease\" class=\"medical medical_review\">Diagnostic approach to the adult with cystic lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-diffuse-lung-disease-by-conventional-chest-radiography\" class=\"medical medical_review\">Evaluation of diffuse lung disease by conventional chest radiography</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">High resolution computed tomography of the lungs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=idiopathic-interstitial-pneumonias-clinical-manifestations-and-pathology\" class=\"medical medical_review\">Idiopathic interstitial pneumonias: Clinical manifestations and pathology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lung-transplantation-general-guidelines-for-recipient-selection\" class=\"medical medical_review\">Lung transplantation: General guidelines for recipient selection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-smoking-cessation-management-in-adults\" class=\"medical medical_review\">Overview of smoking cessation management in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-idiopathic-pulmonary-fibrosis\" class=\"medical medical_review\">Pathogenesis of idiopathic pulmonary fibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer\" class=\"medical medical_review\">Personalized, genotype-directed therapy for advanced non-small cell lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-bronchiolitis-associated-interstitial-lung-disease\" class=\"medical medical_review\">Respiratory bronchiolitis-associated interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of lung biopsy in the diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">Treatment of Langerhans cell histiocytosis</a></li></ul></div></div>","javascript":null}